Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GW003 in Metastatic Tumors
NCT02156388Phase 1Completed
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Aug 2013
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of gw003 in neutropenia (8 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Number of participants with adverse event. Started Aug 2013; status: completed.
02
Drugs
gw003
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02156388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156388.